FDA slaps hold on Cellectis’ off-the-shelf myeloma CAR-T trial after patient death
The patient, who had been enrolled in the Phase I study at the higher dose level of UCARTCS1A, suffered a cardiac arrest, the causes of which are under investigation, the company said.
